R&D | April 22, 2026
New brain study reveals why alcohol relapse remains a persistent challenge
These findings help explain how relapse-triggering memories can persist alongside those that support recovery
These findings help explain how relapse-triggering memories can persist alongside those that support recovery
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
Improvements were also seen in complete response rates, duration of response, and time to next treatment
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Approval is based on positive data from the Phase 3 ECHELON-3 trial
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Subscribe To Our Newsletter & Stay Updated
